Clinical Trial Update: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• SurVaxM (SurVaxM)
• Temozolomide (Temozolomide)

Snippet

Sponsor: MimiVax, LLC | Conditions: Newly Diagnosed Glioblastoma | Phase 2 | Status: UNKNOWN